An interventional study of Later-line therapy in Pancreatic Cancer and Locally Advanced, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-12.
Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer. The main questions it aims to answer are:
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's planned enrollment of 100 is above the median of 46 across 2,424 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy.
Drug: Later-line therapy
Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy.
Another chemotherapy regimen, targeted therapy, or immunotherapy
Resection rate
Proportion of patients who receive surgical resection
Time frame: Baseline until operation, PD or death, whichever occurs first (up to approximately 24 months)
Overall survival
The date of conversion therapy initiation to death due to any cause.
Time frame: Baseline until PD or death, whichever occurs first (up to approximately 24 months)
Progression-free survival
The date of conversion therapy initiation to tumor progression or death due to any cause in the absence of progression.
Time frame: Baseline until PD or death, whichever occurs first (up to approximately 24 months)
R0 resection rate
Proportion of patients who receive R0 surgical resection
Time frame: Baseline until operation, PD or death, whichever occurs first (up to approximately 24 months)
Major pathological response
≤10% of the viable tumor cell in resected sample
Time frame: Baseline until operation, PD or death, whichever occurs first (up to approximately 24 months)
The prognostic value of MRD
The prognostic value of baseline MRD and dynamic MRD changes
Time frame: Baseline until PD or death, whichever occurs first (up to approximately 24 months)
The prognostic role of targeted therapy selected based on MRD
The prognostic role of targeted therapy selected based on MRD
Time frame: Baseline until PD or death, whichever occurs first (up to approximately 24 months)
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital